Skip Navigation

European Heart Journal 1992 13(11):1528-1533;
Copyright © 1992 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by PERMANETTER, B.
Right arrow Articles by BLOMER, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PERMANETTER, B.
Right arrow Articles by BLOMER, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1992 The European Society of Cardiology

Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy

B. PERMANETTER, W. RÖSSY, G. KLEIN, F. WEINGARTNER, K. F. SEIDL and H. BLOMER

First Department of Internal Medicine, Technical University of Munich Klinikum Rechts der Isar, Munich, Germany

Received 18 February 1991; revised 16 April 1992; .

Correspondence to Dr. Bernhard Permanetter, Klinikum Rechts der Isar Ismaninger Str 22, D 8000 Munich 80, Germany

Abstract

Using a placebo-controlled, double-blind cross-over study the potential therapeutic effect of ubiquinone (coenzyme Q10) was investigated in 25 patients suffering from idiopathic dilated cardiomyopathy (New York Heart Association functional classification I, II and III). Over an initial period of 4 months, 15 patients were administered verum (3x33·3 mg coenzyme Q10 . day 1 p.o.) and subsequently given a placebo during the ensuing 4 months (V/P). The sequence of treatment was reversed within the remaining 10 patients (P/V). Therapeutic efficacy was assessed by means of echocardiogram, chest X-ray, radionuclide ventriculography in combination with exercise test and impedance cardiography.

Control values for left ventricular function parameters were similar in both groups; left ventricular ejection fraction: 39·5±11·5% (P/V), 37·6±17·0% (V/P); left ventricular end-diastolic diameter: 65±9 mm (P/V), 67±8mm (P/V); and cardiac output: 5·1±1·41. min–1 (P/V), 5·1±1·11. min–1 (V/P). Chronic treatment with ubiquinone had no influence on haemodynamic parameters, electrocardiogram, incidence of ventricular arrhythmias or on exercise tolerance. It was therefore impossible to demonstrate any therapeutic effect of ubiquinone in patients suffering from idiopathic dilated cardiomvopathy.

Key Words: Ubiquinone • coenzyme Q10 • chronic treatment • idiopathic dilated cardiomyopathy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nutr Clin PractHome page
S. P. Dunn, B. Bleske, M. Dorsch, T. Macaulay, B. Van Tassell, and O. Vardeny
Nutrition and Heart Failure: Impact of Drug Therapies and Management Strategies
Nutr Clin Pract, February 1, 2009; 24(1): 60 - 75.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. L. Molyneux, C. M. Florkowski, P. M. George, A. P. Pilbrow, C. M. Frampton, M. Lever, and A. M. Richards
Coenzyme Q10: An Independent Predictor of Mortality in Chronic Heart Failure
J. Am. Coll. Cardiol., October 28, 2008; 52(18): 1435 - 1441.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. van der Harst, A. A. Voors, W. H. van Gilst, M. Bohm, and D. J. van Veldhuisen
Statins in the treatment of chronic heart failure: Biological and clinical considerations
Cardiovasc Res, August 1, 2006; 71(3): 443 - 454.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
L. Tavazzi, G. Tognoni, M. G. Franzosi, R. Latini, A. P. Maggioni, R. Marchioli, G. L. Nicolosi, M. Porcu, and on behalf of the GISSI-HF investigators
Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure
Eur J Heart Fail, August 1, 2004; 6(5): 635 - 641.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. Mak and G. E. Newton
The Oxidative Stress Hypothesis of Congestive Heart Failure : Radical Thoughts
Chest, December 1, 2001; 120(6): 2035 - 2046.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
C. Crone, G. Gabriel, and T. N. Wise
Non-Herbal Nutritional Supplements--The Next Wave: A Comprehensive Review of Risks and Benefits for the C-L Psychiatrist
Psychosomatics, August 1, 2001; 42(4): 285 - 299.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. K. A. Witte, A. L. Clark, and J. G. F. Cleland
Chronic heart failure and micronutrients
J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1765 - 1774.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
M. Khatta, B. S. Alexander, C. M. Krichten, M. L. Fisher, R. Freudenberger, S. W. Robinson, and S. S. Gottlieb
The Effect of Coenzyme Q10 in Patients with Congestive Heart Failure
Ann Intern Med, April 18, 2000; 132(8): 636 - 640.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. H. Langsjoen
Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure
J. Am. Coll. Cardiol., March 1, 2000; 35(3): 816 - 817.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. K Singal, N. Khaper, V. Palace, and D. Kumar
On the role of coenzyme Q10 in cardiovascular diseases
Cardiovasc Res, July 1, 1999; 43(1): 250 - 251.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.